Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutritions Ltd manufactures and trades Pharmaceutical, Nutraceutical, Herbal and Ayurvedic commodities[1]
- Market Cap ₹ 40.5 Cr.
- Current Price ₹ 43.1
- High / Low ₹ 55.0 / 39.5
- Stock P/E 17.4
- Book Value ₹ 17.6
- Dividend Yield 0.00 %
- ROCE 16.1 %
- ROE 15.1 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 57.9 days to 42.2 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.2% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
6.07 | 26.76 | 35.14 | 62.52 | 71.76 | |
5.61 | 25.74 | 31.65 | 57.77 | 66.04 | |
Operating Profit | 0.46 | 1.02 | 3.49 | 4.75 | 5.72 |
OPM % | 7.58% | 3.81% | 9.93% | 7.60% | 7.97% |
0.00 | 0.02 | 0.32 | 0.22 | 0.27 | |
Interest | 0.18 | 0.48 | 0.79 | 0.67 | 0.29 |
Depreciation | 0.12 | 0.28 | 1.91 | 1.81 | 1.82 |
Profit before tax | 0.16 | 0.28 | 1.11 | 2.49 | 3.88 |
Tax % | 6.25% | -32.14% | 27.03% | 22.09% | 27.84% |
0.15 | 0.36 | 0.81 | 1.94 | 2.79 | |
EPS in Rs | 0.22 | 0.42 | 0.65 | 1.68 | 2.47 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 39% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 81% |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 5% |
1 Year: | -26% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 11% |
Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 |
Reserves | 1.44 | 6.45 | 7.17 | 9.49 | 7.17 |
7.49 | 7.25 | 10.30 | 8.30 | 7.85 | |
5.73 | 9.85 | 12.29 | 14.67 | 22.98 | |
Total Liabilities | 18.00 | 28.09 | 34.30 | 37.16 | 47.39 |
1.70 | 2.01 | 10.13 | 10.20 | 10.69 | |
CWIP | 1.22 | 4.48 | 0.02 | 0.02 | 0.00 |
Investments | 0.00 | 0.49 | 0.02 | 1.88 | 1.88 |
15.08 | 21.11 | 24.13 | 25.06 | 34.82 | |
Total Assets | 18.00 | 28.09 | 34.30 | 37.16 | 47.39 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-0.31 | -1.08 | 1.10 | 5.35 | 4.06 | |
-2.02 | -6.14 | -3.44 | -3.61 | -2.30 | |
2.95 | 6.71 | 2.42 | -1.77 | -0.68 | |
Net Cash Flow | 0.62 | -0.51 | 0.07 | -0.03 | 1.08 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 430.54 | 124.26 | 129.63 | 78.46 | 107.73 |
Inventory Days | 369.26 | 103.22 | 128.73 | 67.15 | 67.85 |
Days Payable | 455.40 | 135.07 | 143.88 | 72.94 | 108.50 |
Cash Conversion Cycle | 344.41 | 92.41 | 114.48 | 72.67 | 67.07 |
Working Capital Days | 316.29 | 61.65 | 87.87 | 43.55 | 42.17 |
ROCE % | 4.85% | 8.78% | 12.75% | 16.08% |
Documents
Announcements
-
General Updates
3 September 2025 - Book closure 18–25 Sep 2025; cutoff 3 Sep and 18 Sep 2025 for 5th AGM notices/e-voting.
-
Change in Director(s)
3 September 2025 - Re-appointment of Kalpesh Ladhawala (MD) and Tanmaykumar Shah (WTD) for Jan 20, 2026–Jan 19, 2029; AGM Sept 25, 2025.
-
Shareholders meeting
3 September 2025 - Annual report filed; AGM 25 Sept 2025; MD/WTD reappointments; approve related-party transactions up to Rs.100 Crore each.
-
Outcome of Board Meeting
3 September 2025 - Board approved reappointments of MD and Whole-time Director for Jan 20, 2026–Jan 19, 2029; AGM on Sept 25, 2025.
-
Outcome of Board Meeting
3 September 2025 - Board approved re-appointment of Kalpesh Ladhawala and Tanmaykumar Shah for 20 Jan 2026–19 Jan 2029; AGM 25 Sep 2025.
Business Overview:[1]
Company manufactures and sells Nutraceutical and Herbal dietary supplement formulations, ingredients and research. It manufactures private label brands for different companies and its own brands, selling through online and direct channels. Company is a specialized Contract manufacturer for different formulation in Nutraceuticals and Herbal products